CHARLES BROWN: Open Payments
NPI 1487803003 · BALTIMORE, MD. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,340 in 61 payments from 15 companies in 2025. Trend: 2023 $1,137 · 2024 $1,620 · 2025 $1,340
Food & beverage: $1,274Education: $66
| Company | Payments | Amount |
|---|---|---|
| Janssen Biotech, Inc. | 12 | $299 |
| ABBVIE INC. | 12 | $203 |
| LEO Pharma Inc. | 6 | $118 |
| GENZYME CORPORATION | 3 | $114 |
| UCB, Inc. | 3 | $96 |
| PFIZER INC. | 5 | $95 |
| Regeneron Healthcare Solutions, Inc. | 3 | $81 |
| Novartis Pharmaceuticals Corporation | 3 | $77 |
| Incyte Corporation | 3 | $68 |
| Amgen Inc. | 4 | $67 |
Products named: TREMFYA, DUPIXENT, RINVOQ, SKYRIZI, Bimzelx, CIBINQO, OPZELURA, OTEZLA.
Industry payments across MD — which companies pay providers there.
